PIK3CA and breast cancer: Taken together, it is worth perusing clinical trials with triple combinations (CDK4/6 inhibitors plus alpelisib or everolimus plus antiestrogen) in a neoadjuvant setting to improve pCR with HR+/HER2−/PIK3CA-mutated BC patients.